Minerva Neurosciences (NERV) Other Gross PP&E Adjustments (2013 - 2026)
Minerva Neurosciences posted quarterly Other Gross PP&E Adjustments of -$504777.0 for Q1 2026, up 1.77% year-on-year from -$496021.6 in Q1 2025, and up 20.83% on a QoQ basis from -$637566.0 in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Other Gross PP&E Adjustments data on file, last reported at -$504777.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 1.77% year-over-year to -$504777.0; the trailing twelve-month figure through Mar 2026 stood at -$1.8 million (up 82.59% YoY), and the FY2025 full-year result was -$637566.0, up 92.8% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$504777.0, up from -$637566.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$95083.0 in Q1 2023 and bottomed at -$10.0 million in Q4 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$381775.0 (2024), against an average of -$1.9 million.
- Peak annual rise in Other Gross PP&E Adjustments reached 92.8% in 2025, while the deepest fall reached 328.87% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$10.0 million in 2022, then grew by 11.23% to -$8.9 million in 2023, then rose by 0.57% to -$8.9 million in 2024, then soared by 92.8% to -$637566.0 in 2025, then rose by 20.83% to -$504777.0 in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$504777.0 (Q1 2026), -$637566.0 (Q4 2025), and -$197087.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -504,777.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -504,777.00 |
| Mar 31, 2026 | -504,777.00 |
| Dec 31, 2025 | -637,566.00 |
| Dec 31, 2025 | -637,566.00 |
| Sep 30, 2025 | -197,087.00 |
| Sep 30, 2025 | -197,087.00 |
| Jun 30, 2025 | -435,882.00 |
| Jun 30, 2025 | -435,882.00 |
| Mar 31, 2025 | -513,847.00 |
| Mar 31, 2025 | -513,847.00 |
| Dec 31, 2024 | -8.86 Mn |
| Dec 31, 2024 | -8.86 Mn |
| Sep 30, 2024 | -441,536.00 |
| Sep 30, 2024 | -441,536.00 |
| Jun 30, 2024 | -381,775.00 |
| Jun 30, 2024 | -381,775.00 |
| Mar 31, 2024 | -119,814.00 |
| Mar 31, 2024 | -119,814.00 |
| Dec 31, 2023 | -8.91 Mn |
| Dec 31, 2023 | -8.91 Mn |
| Sep 30, 2023 | -128,225.00 |
| Sep 30, 2023 | -128,225.00 |
| Jun 30, 2023 | -305,848.00 |
| Jun 30, 2023 | -305,848.00 |
| Mar 31, 2023 | -95,083.00 |
| Mar 31, 2023 | -95,083.00 |
| Dec 31, 2022 | -10.04 Mn |
| Dec 31, 2022 | -10.04 Mn |
| Sep 30, 2022 | -338,129.00 |
| Sep 30, 2022 | -338,129.00 |
| Jun 30, 2022 | -185,285.00 |
| Jun 30, 2022 | -185,285.00 |
| Mar 31, 2022 | -115,912.00 |
| Mar 31, 2022 | -115,912.00 |
| Dec 31, 2021 | -8.95 Mn |
| Dec 31, 2021 | -8.95 Mn |
| Sep 30, 2021 | -227,874.00 |
| Sep 30, 2021 | -227,874.00 |
| Jun 30, 2021 | -364,861.00 |
| Jun 30, 2021 | -364,861.00 |
| Mar 31, 2021 | -265,042.00 |
| Mar 31, 2021 | -265,042.00 |
| Dec 31, 2020 | -9.61 Mn |
| Dec 31, 2020 | -9.61 Mn |
| Sep 30, 2020 | -209,514.00 |
| Sep 30, 2020 | -209,514.00 |
| Jun 30, 2020 | -437,486.00 |
| Jun 30, 2020 | -437,486.00 |
| Mar 31, 2020 | -504,553.00 |
| Mar 31, 2020 | -504,553.00 |
| Dec 31, 2019 | -7.78 Mn |
| Dec 31, 2019 | -7.78 Mn |
| Sep 30, 2019 | -674,246.00 |
| Sep 30, 2019 | -674,246.00 |
| Jun 30, 2019 | -922,699.00 |
| Jun 30, 2019 | -922,699.00 |
| Mar 31, 2019 | -766,867.00 |
| Mar 31, 2019 | -766,867.00 |
| Dec 31, 2018 | -5.53 Mn |
| Dec 31, 2018 | -5.53 Mn |
| Sep 30, 2018 | -332,437.00 |
| Sep 30, 2018 | -332,437.00 |
| Jun 30, 2018 | -372,139.00 |
| Jun 30, 2018 | -372,139.00 |
| Mar 31, 2018 | -455,545.00 |
| Mar 31, 2018 | -455,545.00 |
| Dec 31, 2017 | -4.18 Mn |
| Dec 31, 2017 | -4.18 Mn |
| Sep 30, 2017 | -334,752.00 |
| Sep 30, 2017 | -334,752.00 |
| Jun 30, 2017 | -527,048.00 |
| Jun 30, 2017 | -527,048.00 |
| Mar 31, 2017 | -213,213.00 |
| Mar 31, 2017 | -213,213.00 |
| Dec 31, 2016 | -4.74 Mn |
| Dec 31, 2016 | -4.74 Mn |
| Sep 30, 2016 | -192,000.00 |
| Sep 30, 2016 | -192,000.00 |
| Jun 30, 2016 | -30,000.00 |
| Jun 30, 2016 | -30,000.00 |
| Dec 31, 2015 | -3.66 Mn |
| Dec 31, 2015 | -3.66 Mn |
| Sep 30, 2015 | -86,422.00 |
| Sep 30, 2015 | -86,422.00 |
| Mar 31, 2015 | -128,446.00 |
| Mar 31, 2015 | -128,446.00 |
| Dec 31, 2014 | -2.96 Mn |
| Dec 31, 2014 | -2.96 Mn |
| Sep 30, 2014 | -70,445.00 |
| Sep 30, 2014 | -70,445.00 |
| Dec 31, 2013 | -595,215.00 |
| Dec 31, 2013 | -595,215.00 |